Zhiqiang Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhiqiang Feng has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Ke Wang
Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Xiannongtan Street, Beijing, 100050, PR China
6 shared publications- Xiaoguang Chen
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
6 shared publications Xinyan Dai
Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Xiannongtan Street, Beijing, 100050, PR China
5 shared publicationsHao Chen
Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
4 shared publicationsLei Lei
The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
3 shared publicationsXupeng Huang
Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
3 shared publications
Latest Publications
- 9 May 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 314, 118929
Corrigendum to ‘Synthesis and structure-activity relationships of N - (3 - (1H-imidazol-2-yl) phenyl) - 3-phenylpropionamide derivatives as a novel class of covalent inhibitors of p97/VCP ATPase’ [ Eur. J. Med. Chem. 248 (2023) 115094]
- 9 May 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 314, 118929
Corrigendum to ‘Synthesis and structure-activity relationships of N - (3 - (1H-imidazol-2-yl) phenyl) - 3-phenylpropionamide derivatives as a novel class of covalent inhibitors of p97/VCP ATPase’ [ Eur. J. Med. Chem. 248 (2023) 115094]
- Open Access
- 9 May 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (7) , 3178-3179
Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]
- 9 May 2023
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (7) , 3178-3179
Open AccessAuthor correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]
- Open Access
- 4 March 2022
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 12 (6) , 2845-2858
YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer
- 4 March 2022
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 12 (6) , 2845-2858
Open AccessYPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer
- 1 November 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 52, 128403
Design, synthesis, and structure–activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold
- 1 November 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 52, 128403
Design, synthesis, and structure–activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold
- 1 September 2021
- Published by Elsevier in Bioorganic Chemistry
- Vol. 114, 105034
Design, synthesis, and biological evaluation of 1-methyl-1H-pyrazolo[4,3-b]pyridine derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction
- 1 September 2021
- Published by Elsevier in Bioorganic Chemistry
- Vol. 114, 105034
Design, synthesis, and biological evaluation of 1-methyl-1H-pyrazolo[4,3-b]pyridine derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction
- Open Access
- 7 April 2021
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 11 (22) , 13119-13123
Palladium-catalyzed one-pot synthesis of 2-substituted quinazolin-4(3 H )-ones from o -nitrobenzamide and alcohols
Palladium-catalyzed 2-substituted quinazolin-4(3H)-one formation from readily available o-nitrobenzamides and alcohols using hydrogen transfer is described. Various quinazolin-4(3H)-ones were obtained in good to high yields. The cascade reaction including alcohol oxidation, nitro reduction, condensation, and dehydrogenation occurs without any added reducing or oxidizing agent.
- 7 April 2021
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 11 (22) , 13119-13123
Open AccessPalladium-catalyzed one-pot synthesis of 2-substituted quinazolin-4(3 H )-ones from o -nitrobenzamide and alcohols
Palladium-catalyzed 2-substituted quinazolin-4(3H)-one formation from readily available o-nitrobenzamides and alcohols using hydrogen transfer is described. Various quinazolin-4(3H)-ones were obtained in good to high yields. The cascade reaction including alcohol oxidation, nitro reduction, condensation, and dehydrogenation occurs without any added reducing or oxidizing agent.